

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4510058

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
MEDICIS PHARMACEUTICAL CORPORATION		07/17/2017
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	THE BANK OF NEW YORK MELLON	
<b>Street Address:</b>	101 BARCLAY STREET	
<b>Internal Address:</b>	FLOOR 7E	
<b>City:</b>	NEW YORK	
<b>State/Country:</b>	NEW YORK	
<b>Postal Code:</b>	10286	
<b>PROPERTY NUMBERS Total: 87</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	13659789	
<b>Patent Number:</b>	6765001	
<b>Patent Number:</b>	8232264	
<b>Patent Number:</b>	7771733	
<b>Patent Number:</b>	7794738	
<b>Patent Number:</b>	7217422	
<b>Patent Number:</b>	7220424	
<b>Patent Number:</b>	8354424	
<b>Patent Number:</b>	8436176	
<b>Patent Number:</b>	6797716	
<b>Patent Number:</b>	6949646	
<b>Patent Number:</b>	7038051	
<b>Patent Number:</b>	7335773	
<b>Patent Number:</b>	7678918	
<b>Patent Number:</b>	7928116	
<b>Patent Number:</b>	7915277	
<b>Patent Number:</b>	7902242	
<b>Patent Number:</b>	7915278	
<b>Patent Number:</b>	7915279	

PATENT

Property Type	Number
Patent Number:	7902210
Patent Number:	8080560
Patent Number:	7902212
Patent Number:	7906524
Patent Number:	7902243
Patent Number:	7902244
Patent Number:	7939555
Patent Number:	7906525
Patent Number:	7902213
Patent Number:	7906527
Patent Number:	7902215
Patent Number:	7928118
Patent Number:	7655672
Patent Number:	7902216
Patent Number:	7902245
Patent Number:	7923463
Patent Number:	7902246
Patent Number:	8557838
Patent Number:	7906543
Patent Number:	7919501
Patent Number:	7902209
Patent Number:	7928117
Patent Number:	7902211
Patent Number:	7906526
Patent Number:	7902214
Patent Number:	9492682
Application Number:	13168796
Patent Number:	8642616
Patent Number:	9078889
Application Number:	14796296
Patent Number:	8222270
Patent Number:	8236816
Patent Number:	8299109
Patent Number:	9370509
Application Number:	15187751
Patent Number:	8426457
Patent Number:	8946274
Patent Number:	9072876

Property Type	Number
Application Number:	14641089
Patent Number:	8598196
Patent Number:	9271973
Application Number:	13895305
Application Number:	13536130
Application Number:	15410428
Patent Number:	8722650
Patent Number:	9192615
Patent Number:	8252776
Patent Number:	7544373
Patent Number:	7541347
Patent Number:	7919483
Patent Number:	7790705
Patent Number:	8268804
Patent Number:	5908838
Patent Number:	8901146
Patent Number:	7311679
Patent Number:	6028105
Application Number:	13421727
Application Number:	13199113
Application Number:	14213530
Application Number:	13890173
Patent Number:	9119793
Patent Number:	6469033
Patent Number:	7981909
Patent Number:	8227490
Patent Number:	7026337
Patent Number:	5932612
Patent Number:	6057360
Application Number:	13672520

#### CORRESPONDENCE DATA

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2023704750

**Email:** ipteam@coagencyglobal.com

**Correspondent Name:** DARLENA BARI STARK

**Address Line 1:** 1025 VERMONT AVE NW, SUITE 1130

**Address Line 2:** COGENCY GLOBAL INC.

**PATENT**

**REEL: 043239 FRAME: 0677**

<b>Address Line 4:</b> WASHINGTON, D.C. 20005	
<b>ATTORNEY DOCKET NUMBER:</b>	F171430
<b>NAME OF SUBMITTER:</b>	EMILY OHANNESSIAN
<b>SIGNATURE:</b>	/Emily Ohannessian/
<b>DATE SIGNED:</b>	07/19/2017
<b>Total Attachments: 15</b> source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page2.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page3.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page4.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page5.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page6.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page7.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page8.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page9.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page10.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page11.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page12.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page13.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page14.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page15.tif source=#89890110v1 - (MEDICIS PHARMACEUTICAL CORPORATION - patent SA)#page16.tif	

## **PATENT SECURITY AGREEMENT**

This **PATENT SECURITY AGREEMENT**, dated as of July 17, 2017 (as it may be amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”), is made by the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) in favor of The Bank of New York Mellon, as notes collateral agent for the First Lien Notes Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Collateral Agent**”).

**WHEREAS**, the Grantors are party to the Indenture dated as of March 21, 2017 (the “**Indenture**”) between Valeant Pharmaceuticals International, Inc., each of the Grantors and the other grantors party thereto and the Collateral Agent pursuant to which the Grantors granted a security interest to the Collateral Agent in the Patent Collateral (as defined below) and are required to execute and deliver this Agreement.

**NOW, THEREFORE**, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

### **SECTION 1. Defined Terms**

Unless otherwise defined herein, terms defined in the Indenture and used herein have the meaning given to them in the Indenture.

### **SECTION 2. Grant of Security Interest**

Each Grantor hereby grants to the Collateral Agent, for the benefit of the First Lien Notes Secured Parties, a security interest in and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether now owned or hereafter acquired by such Grantor or in which any Grantor now has or hereafter acquires any right, title or interest and wherever the same may be located (collectively, the “**Patent Collateral**”):

all United States and foreign patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application listed in Schedule A attached hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof, (iii) all patentable inventions and improvements thereto, (iv) the right to sue or otherwise recover for any past, present and future infringement or other violation thereof, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world, but in any case excluding any Excluded Assets.

### **SECTION 3. Security Agreement**

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Notes Collateral Agent for the First Lien Notes Secured Parties, pursuant to the Indenture, and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Indenture, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Indenture, the provisions of the Indenture shall control.

#### **SECTION 4. Governing Law**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.


#### **SECTION 5. Counterparts**

This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]

**IN WITNESS WHEREOF**, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**MEDICIS PHARMACEUTICAL CORPORATION**

By:   
Name: Linda LaGorga  
Title:

Accepted and Agreed:  
**THE BANK OF NEW YORK MELLON**  
as Collateral Agent

By: Joellen F. McNamara  
Name:  
Title: **Joellen F. McNamara**  
**Vice President**

---

[Signature Page to Patent Security Agreement]

**PATENT**  
**REEL: 043239 FRAME: 0682**



**MEDICIS PHARMACEUTICAL CORPORATION**

**SCHEDULE 1**

<b>Country</b>	<b>Status</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Publ. No.</b>	<b>Publ. Date</b>	<b>Patent No.</b>	<b>Title</b>	<b>Current Owner</b>
United States	PENDING	13/659789	10/24/2012				TOPICAL FLUNISOLIDE COMPOSITIONS AND METHODS OF TREATMENT	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	10/037360	12/21/2001	2003-0130247-A1	7/10/2003	6765001	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/322346	1/29/2009	2009-0176750-A1	7/9/2009	8232264	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/657880	1/24/2007	2007-0142343-A1	6/21/2007	7771733	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/657893	1/24/2007	2007-0142344-A1	6/21/2007	7794738	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	10/407354	4/4/2003	2003-0186951-A1	10/2/2003	7217422	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	10/407380	4/4/2003	2003-0176408-A1	9/18/2003	7220424	COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/886204	3/14/2006	2008-0262022-A1	10/23/2008	8354424	METHOD OF TREATING ACTINIC KERATOSIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/794584	12/28/2005	2008-0306266-A1	12/11/2008	8436176	PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE	MEDICIS PHARMACEUTICAL CORPORATION

United States	ISSUED	10/406181	4/3/2003	2004-00239 32-A1	2/5/2004	6797716	IMIDAZONAPHTH YRIDINES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/004674	12/3/2004	2005-01074 21-A1	5/19/2005	6949646	IMIDAZONAPHTH YRIDINES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/188418	7/25/2005	2005-02883 20-A1	12/29/2005	7038051	IMIDAZONAPHTH YRIDINES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/276074	2/13/2006	2006-01286 74-A1	6/15/2006	7335773	IMIDAZONAPHTH YRIDINES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/999602	12/6/2007	2008-00910 10-A1	4/17/2008	7678918	INTERMEDIATES FOR IMIDAZONAPHTH YRIDINES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697185	1/29/2010	US 2010-01208 20 A1	5/13/2010	7928116	METHOD OF TREATING ACTINIC KERATOSIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697210	1/30/2010	US 2010-01208 21 A1	5/13/2010	7915277	METHOD OF TREATING GENITAL OR PERI-ANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697217	1/30/2010	US 2010-01305 29 A1	5/27/2010	7902242	METHOD OF STABILIZING IMIQUIMOD	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697246	1/30/2010	US 2010-01208 23 A1	5/13/2010	7915278	METHOD OF TREATING BASAL CELL CARCINOMA	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697294	1/30/2010	US 2010-01208 25 A1	5/13/2010	7915279	METHOD OF TREATING MOLLESCUM CONTAGIOSUM	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697412	1/30/2010	US 2010-01208 27 A1	5/13/2010	7902210	REDUCTION OF IMIQUIMOD IMPURITIES AT TWO MONTHS USING REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/276324	2/24/2006	2007-01235 58-A1	5/31/2007	8080560	Immune response modifier formulations containing oleic acid and methods	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697417	2/1/2010	US 2010-01208 29 A1	5/13/2010	7902212	REDUCTION OF IMIQUIMOD IMPURITIES AT SIX MONTHS USING REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION

United States	ISSUED	12/697423	2/1/2010	2010-01208 30-A1	5/13/2010	7906524	PHARMACEUTICAL CREAM HAVING SIMILAR OR LESS LEVELS OF IMIQUIMOD IMPURITY FORMATION AS CREAM WITH BHA (COMPARATOR)	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697429	2/1/2010	US 2010-01208 31 A1	5/13/2010	7902243	METHODS FOR IMPROVING IMIQUIMOD AVAILABILITY AT TWO MONTHS, FOUR MONTHS AND SIX MONTHS BETWEEN REFINED AND COMPENDIAL	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697434	2/1/2010	US 2010-01208 32 A1	5/13/2010	7902244	METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST FOUR MONTHS STORAGE)	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697439	2/1/2010	US 2010-01208 33 A1	5/13/2010	7939555	METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697580	2/1/2010	2010-01208 34-A1	5/13/2010	7906525	REDUCTION OF IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697972	2/1/2010	US 2010-01208 35 A1	5/13/2010	7902213	PHARMACEUTICAL CREAM WITH REDUCED IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION

United States	ISSUED	12/698069	2/1/2010	2010-0130530-A1	5/27/2010	7906527	REDUCTION OF IMIQUIMOD IMPURITIES USING REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698096	2/1/2010	US 2010-0130531 A1	5/27/2010	7902215	PHARMACEUTICAL CREAMS WITH REDUCED IMIQUIMOD IMPURITIES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698113	2/1/2010	US 2010-0130532 A1	5/27/2010	7928118	REDUCTION OF IMIQUIMOD IMPURITIES IN PHARMACEUTICAL CREAMS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/334255	12/12/2008	2009-0093514-A1	4/9/2009	7655672	IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698116	2/1/2010	US 2010-0130533 A1	5/27/2010	7902216	PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACID	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698120	2/1/2010	US 2010-0130534 A1	5/27/2010	7902245	METHODS FOR REDUCING IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698123	2/1/2010	US 2010-0130535 A1	5/27/2010	7923463	METHODS FOR STABILIZING IMIQUIMOD FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698132	2/1/2010	US 2010-0130536 A1	5/27/2010	7902246	METHODS FOR CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/279696	10/24/2011	2012-0237551-A1	9/20/2012	8557838	METHODS FOR CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES FOR TWO MONTHS,	MEDICIS PHARMACEUTICAL CORPORATION

							FOUR MONTHS, AND SIX MONTHS	
United States	ISSUED	12/697163	1/29/2010	2010-0120819-A1	5/13/2010	7906543	IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697244	1/30/2010	2010-0120822-A1	5/13/2010	7919501	METHOD OF CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697278	1/31/2010	2010-0120824 A1	5/13/2010	7902209	METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697296	1/31/2010	2010-0120826-A1	5/13/2010	7928117	METHOD OF INDUCING CYTOKINE BIOSYNTHESIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/697415	2/1/2010	2010-0120828-A1	5/13/2010	7902211	METHOD OF INDUCING INTERFERON BIOSYNTHESIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698011	2/1/2010	2010-0120836 A1	5/13/2010	7906526	METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITION	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/698039	2/1/2010	US 2010-0120837 A1	5/13/2010	7902214	METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITION	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/619983	9/14/2012	2013-0190715-A1	7/25/2013	9492682	COMBINATION THERAPY WITH LOW DOSAGE STRENGTH IMIQUIMOD AND PHOTODYNAMIC THERAPY TO TREAT ACTINIC KERATOSIS	MEDICIS PHARMACEUTICAL CORPORATION

United States	PUBLISHED	13/168796	6/24/2011	2011-0319811-A1	12/29/2011		COMBINATION THERAPY WITH CRYOSURGERY AND LOW DOSAGE STRENGTH IMIQUIMOD TO TREAT ACTINIC KERATOSIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/559473	7/26/2012	2012-0289538-A1	11/15/2012	8642616	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	14/091965	11/27/2013	2014-0187575-A1	7/3/2014	9078889	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	14/796296	7/10/2015	2015-0328206-A1	11/19/2015		LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/179315	7/8/2011	2011-0257216-A1	10/20/2011	8222270	2 x 2 x 2 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD	MEDICIS PHARMACEUTICAL CORPORATION

United States	ISSUED	13/181499	7/12/2011	2011-02572 18-A1	10/20/2011	8236816	2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/182433	7/13/2011	2011-02636 35-A1	10/27/2011	8299109	METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/568003	8/6/2012	2013-02108 55-A1	8/15/2013	9370509	2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	15/187751	6/20/2016	2016-03031 11-A1	10/20/2016		2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	10/799999	3/12/2004	2004-01809 19-A1	9/16/2004	8426457	METHODS OF IMPROVING SKIN QUALITY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/608998	9/10/2012	2013-01493 41-A1	6/13/2013	8946274	METHODS OF IMPROVING SKIN QUALITY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/875787	9/3/2010	2012-00355 56-A1	2/9/2012	9072876	PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM	MEDICIS PHARMACEUTICAL CORPORATION

United States	PUBLISHED	14/641089	3/6/2015	2015-03141 15-A1	11/5/2015		PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/552543	7/18/2012	2012-02832 6-A1	11/8/2012	8598196	METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	14/091589	11/27/2013	2014-03235 16-A1	10/30/2014	9271973	METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	13/895305	5/15/2013	2013-02530 03-A1	9/26/2013		METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY	MEDICIS PHARMACEUTICAL CORPORATION
United States	ALLOWED	13/536130	6/28/2012				GASTRORETENTIVE DOSAGE FORMS FOR MINOCYCLINE	MEDICIS PHARMACEUTICAL CORPORATION
United States	PENDING	15/410428	1/19/2017				GASTRORETENTIVE DOSAGE FORMS FOR MINOCYCLINE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/861424	8/23/2010			8722650	EXTENDED-RELEASE	MEDICIS PHARMACEUTICAL



							MINOCYCLINE DOSAGE FORMS	CORPORATION
United States	ISSUED	12/536359	8/5/2009	2010-00035 846-A1	2/11/2010	9192615	METHOD FOR THE TREATMENT OF ACNE AND CERTAIN DOSAGE FORMS THEREOF	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/695513	4/2/2007	2008-02412 41-A1	10/2/2008	8252776	MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/695539	4/2/2007	2008-02412 36-A1	10/2/2008	7544373	MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/695528	4/2/2007	2008-02426 41-A1	10/2/2008	7541347	MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/166817	6/24/2005	2006-02932 90-A1	12/28/2006	7919483	Method for the Treatment of Acne	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/253845	10/17/2008	2009-00418 46-A1	2/12/2009	7790705	Minocycline Oral Dosage Forms for the Treatment of Acne	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	12/875876	9/3/2010	2010-03301 31-A1	12/30/2010	8268804	Minocycline Oral Dosage Forms for the Treatment of Acne	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	09/028871	6/24/2008			5908838	METHOD FOR THE TREATMENT OF ACNE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/518729	12/22/2010	2013-00180 31-A1	1/17/2013	8901146	AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	11/027491	12/29/2004	2005-01543 13-A1	7/14/2005	7311679	DISPOSABLE TRANSDUCER SEAL	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	08/484548	6/7/1995			6028105	Topical Drug Delivery Composition and Method	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	13/421727	3/15/2012	2012-02389 13-A1	9/20/2012		METHODS OF EVALUATING NORMALCY OF LIPS AND SAFETY OF LIP TREATMENTS	MEDICIS PHARMACEUTICAL CORPORATION

United States	PUBLISHED	13/199113	8/19/2011	2012-0046576-A1	2/23/2012		MID-FACE AESTHETIC SCALE AND RELATED METHOD	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	14/213530	3/14/2014	2014-0274982-A1	9/18/2014		TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT	MEDICIS PHARMACEUTICAL CORPORATION
United States	PUBLISHED	13/890173	5/8/2013	2014-0274970-A1	9/18/2014		CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/536052	6/28/2012			9119793	GASTRORETENTIVE DOSAGE FORMS FOR DOXYCYCLINE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	09/077191	8/21/1998			6469033	USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SKIN DISEASE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/018417	9/16/1997	2011-0112153-A1	5/12/2011	7981909	USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	13/177710	7/7/2011	2011-0269801-A1	11/3/2011	8227490	USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	10/690597	9/16/1997	2004-0081677-A1	4/29/2004	7026337	ANTIMYCOTIC GEL HAVING HIGH ACTIVE COMPOUND RELEASE	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	08/906351	8/5/1997			5932612	COMPOSITION AND SYSTEMS FOR THE TREATMENT OF HYPERPIGMENTATION	MEDICIS PHARMACEUTICAL CORPORATION
United States	ISSUED	09/286405	4/5/1999			6057360	COMPOSITION AND SYSTEMS FOR THE TREATMENT OF HYPERPIGMENTATION	MEDICIS PHARMACEUTICAL CORPORATION

United States	PENDING	13/672520	11/8/2012				AUTOMATED PATIENT ASSISTANCE SYSTEM	MEDICIS PHARMACEUTICAL CORPORATION
---------------	---------	-----------	-----------	--	--	--	-------------------------------------	------------------------------------